OSCAR HEALTH, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.04 USD | -6.19% |
|
-5.05% | +97.16% |
| 06-07 | Oscar Health Insider Sold Shares Worth $328,807, According to a Recent SEC Filing | MT |
| 06-07 | Transcript : Oscar Health, Inc. - Analyst/Investor Day |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 1,645 | 528.3 | 2,066 | 4,274 | - | - |
| Enterprise Value (EV) 1 | 540.7 | -732.3 | 494.5 | 2,167 | 1,515 | 749.4 |
| P/E ratio | -2.45 x | -0.86 x | -7.5 x | 328 x | 28.1 x | 14.1 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 0.61 x | 0.1 x | 0.35 x | 0.48 x | 0.38 x | 0.32 x |
| EV / Revenue | 0.2 x | -0.14 x | 0.08 x | 0.24 x | 0.13 x | 0.06 x |
| EV / EBITDA | -1.26 x | 1.58 x | -10.9 x | 11.1 x | 3.81 x | 1.1 x |
| EV / FCF | - | - | -1.66 x | 2.82 x | 3.26 x | 0.99 x |
| FCF Yield | - | - | -60.2% | 35.5% | 30.7% | 101% |
| Price to Book | 0.99 x | 0.6 x | - | - | - | - |
| Nbr of stocks (in thousands) | 209,516 | 214,755 | 225,797 | 236,909 | - | - |
| Reference price 2 | 7.850 | 2.460 | 9.150 | 18.04 | 18.04 | 18.04 |
| Announcement Date | 22-02-10 | 23-02-09 | 24-02-07 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,648 | 2,713 | 5,335 | 5,865 | 8,992 | 11,269 | 13,279 |
| EBITDA 1 | - | -429.8 | -462.3 | -45.24 | 195.8 | 397.9 | 678.4 |
| EBIT 1 | - | -544.5 | -589.9 | -235.6 | 63.59 | 257.6 | 483.5 |
| Operating Margin | - | -20.07% | -11.06% | -4.02% | 0.71% | 2.29% | 3.64% |
| Earnings before Tax (EBT) 1 | - | -570.6 | -610.1 | -267.3 | 24.3 | 257.4 | 499.4 |
| Net income 1 | - | -572.6 | -606.3 | -270.7 | 26.1 | 224.3 | 428.2 |
| Net margin | - | -21.11% | -11.37% | -4.62% | 0.29% | 1.99% | 3.22% |
| EPS 2 | -4.720 | -3.200 | -2.850 | -1.220 | 0.0550 | 0.6425 | 1.280 |
| Free Cash Flow 1 | - | - | - | -297.7 | 769.5 | 464.8 | 758 |
| FCF margin | - | - | - | -5.08% | 8.56% | 4.13% | 5.71% |
| FCF Conversion (EBITDA) | - | - | - | - | 393.01% | 116.84% | 111.74% |
| FCF Conversion (Net income) | - | - | - | - | 2,948.28% | 207.24% | 177.04% |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 21-02-05 | 22-02-10 | 23-02-09 | 24-02-07 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 705.5 | 1,324 | 1,368 | 1,309 | 1,333 | 1,463 | 1,529 | 1,441 | 1,432 | 2,142 | 2,301 | 2,287 | 2,262 | 2,907 | 2,971 |
| EBITDA 1 | -164 | -37.04 | -75.8 | -160 | -189.7 | 51.07 | 35.57 | -20.28 | -111.6 | 219.3 | 94.27 | 1.506 | -110.5 | 351 | 158.4 |
| EBIT 1 | -196.3 | -68.53 | -106.5 | -192.4 | -222.5 | -25.36 | -6.529 | -58.24 | -145.5 | 185.6 | 61.87 | -37.25 | -150.9 | 269.7 | 127.4 |
| Operating Margin | -27.82% | -5.17% | -7.78% | -14.69% | -16.69% | -1.73% | -0.43% | -4.04% | -10.16% | 8.66% | 2.69% | -1.63% | -6.67% | 9.28% | 4.29% |
| Earnings before Tax (EBT) 1 | -197.9 | - | -111.8 | -195.2 | - | - | - | -64.79 | -150.6 | 178.5 | 50.9 | -48.8 | -156 | 278.1 | 121 |
| Net income 1 | -198.9 | -75.15 | -112.2 | -192.9 | -226 | -39.77 | -15.53 | -65.4 | -150 | 177.4 | 50.35 | -48.05 | -153.5 | 257.3 | 111.9 |
| Net margin | -28.2% | -5.67% | -8.2% | -14.73% | -16.96% | -2.72% | -1.02% | -4.54% | -10.48% | 8.28% | 2.19% | -2.1% | -6.79% | 8.85% | 3.77% |
| EPS 2 | -0.9500 | -0.3600 | -0.5300 | -0.9100 | -1.050 | -0.1800 | -0.0700 | -0.2900 | -0.6600 | 0.6200 | 0.1550 | -0.1675 | -0.5675 | 0.8600 | 0.3700 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 22-02-10 | 22-05-10 | 22-08-11 | 22-11-08 | 23-02-09 | 23-05-09 | 23-08-08 | 23-11-07 | 24-02-07 | 24-05-07 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 1,104 | 1,261 | 1,572 | 2,107 | 2,759 | 3,524 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | -298 | 770 | 465 | 758 |
| ROE (net income / shareholders' equity) | - | -77.5% | -53.2% | -32% | -4.53% | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | 7.920 | 4.120 | - | - | - | - |
| Cash Flow per Share 2 | - | -1.020 | 1.790 | -1.230 | 8.180 | 7.580 | - |
| Capex 1 | - | 25.9 | 29 | 25.6 | 34 | 41 | 47.5 |
| Capex / Sales | - | 0.95% | 0.54% | 0.44% | 0.38% | 0.36% | 0.36% |
| Announcement Date | 21-02-05 | 22-02-10 | 23-02-09 | 24-02-07 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
18.04
USD
Average target price
25.4
USD
Spread / Average Target
+40.80%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +97.16% | 4.27B | |
| +12.56% | 9.58B | |
| +3.79% | 6.73B | |
| +7.83% | 5.57B | |
| -1.22% | 2.33B | |
| +11.60% | 921M | |
| +93.06% | 781M | |
| -8.72% | 138M | |
| -31.36% | 50.7M |
- Stock Market
- Equities
- OSCR Stock
- Financials Oscar Health, Inc.
